{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:59:43Z","timestamp":1794257983231,"version":"4.9.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573905"],"award-info":[{"award-number":["82573905"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473415"],"award-info":[{"award-number":["82473415"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273301"],"award-info":[{"award-number":["82273301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BE2020622"],"award-info":[{"award-number":["BE2020622"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018541","name":"Science Fund for Distinguished Young Scholars of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20240018"],"award-info":[{"award-number":["BK20240018"]}],"id":[{"id":"10.13039\/501100018541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Resistance Updates"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.drup.2025.101343","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:34:32Z","timestamp":1765326872000},"page":"101343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Entinostat overcomes cisplatin resistance in bladder cancer by promoting H3K18la-mediated DHRS2 expression and nuclear translocation to suppress the AKR1C3-androgen axis"],"prefix":"10.1016","volume":"85","author":[{"given":"Guanghui","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6842-5757","authenticated-orcid":false,"given":"Minghao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganlin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2421-7311","authenticated-orcid":false,"given":"Wei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drup.2025.101343_bib1","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1038\/s41467-024-52528-7","article-title":"Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial","volume":"15","author":"Baretti","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2025.101343_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.drup.2025.101343_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176841","article-title":"The role of novel protein acylations in cancer","volume":"979","author":"Cao","year":"2024","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.drup.2025.101343_bib4","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/s41419-024-07321-1","article-title":"Mechanistic insights into SIRT7 and EZH2 regulation of cisplatin resistance in bladder cancer cells","volume":"15","author":"Cao","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2025.101343_bib5","article-title":"Metabolic recoding of NSUN2-mediated m(5)C modification promotes the progression of colorectal cancer via the NSUN2\/YBX1\/m(5)C-ENO1 positive feedback loop","volume":"11","author":"Chen","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.drup.2025.101343_bib6","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41585-023-00761-y","article-title":"The androgen receptor in bladder cancer","volume":"20","author":"Chen","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.drup.2025.101343_bib7","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948467","article-title":"Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion","volume":"21","author":"Chen","year":"2020","journal-title":"EMBO Rep."},{"key":"10.1016\/j.drup.2025.101343_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: from mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.drup.2025.101343_bib9","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.immuni.2024.04.006","article-title":"Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma","volume":"57","author":"De Leo","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.drup.2025.101343_bib10","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1158\/2767-9764.CRC-23-0235","article-title":"AKR1C3 converts castrate and post-abiraterone DHEA-S into testosterone to stimulate growth of prostate cancer cells via 5-androstene-3\u03b2,17\u03b2-Diol","volume":"3","author":"Detlefsen","year":"2023","journal-title":"Cancer Res Commun."},{"key":"10.1016\/j.drup.2025.101343_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241813733","article-title":"GABBR2 as a downstream effector of the androgen receptor induces cisplatin resistance in bladder cancer","volume":"24","author":"Elahi Najafi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2025.101343_bib12","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.cr.7310149","article-title":"HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics","volume":"17","author":"Gallinari","year":"2007","journal-title":"Cell Res."},{"key":"10.1016\/j.drup.2025.101343_bib13","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jprot.2016.10.003","article-title":"Lysine acetylation and cancer: a proteomics perspective","volume":"150","author":"Gil","year":"2017","journal-title":"J. Proteom."},{"key":"10.1016\/j.drup.2025.101343_bib14","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/j.1875-9114.1996.tb02913.x","article-title":"Insights into mechanisms of cisplatin resistance and potential for its clinical reversal","volume":"16","author":"Gosland","year":"1996","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.drup.2025.101343_bib15","doi-asserted-by":"crossref","first-page":"1609951","DOI":"10.3389\/pore.2021.1609951","article-title":"Lactate upregulates the expression of DNA repair genes, causing intrinsic resistance of cancer cells to cisplatin","volume":"27","author":"Govoni","year":"2021","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.drup.2025.101343_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175216","article-title":"The emerging roles of HDACs and their therapeutic implications in cancer","volume":"931","author":"Hai","year":"2022","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.drup.2025.101343_bib17","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/pros.24049","article-title":"AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer","volume":"80","author":"Hertzog","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.drup.2025.101343_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2023.110840","article-title":"Inhibition of aldo-keto reductase 1C3 overcomes gemcitabine\/cisplatin resistance in bladder cancer","volume":"388","author":"Himura","year":"2024","journal-title":"Chem. Biol. Inter."},{"key":"10.1016\/j.drup.2025.101343_bib19","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.canlet.2017.10.023","article-title":"Entinostat reverses cisplatin resistance in esophageal squamous cell carcinoma via down-regulation of multidrug resistance gene 1","volume":"414","author":"Huang","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2025.101343_bib20","doi-asserted-by":"crossref","first-page":"17796","DOI":"10.1021\/acs.jmedchem.4c01817","article-title":"Hydrazide-based class i selective hdac inhibitors completely reverse chemoresistance synergistically in platinum-resistant solid cancer cells","volume":"67","author":"Kraft","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drup.2025.101343_bib21","first-page":"176","article-title":"The ADAM9\/UBN2\/AKR1C3 axis promotes resistance to androgen-deprivation in prostate cancer","volume":"12","author":"Le","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.drup.2025.101343_bib22","article-title":"Histone demethylase KDM7A regulates androgen receptor activity, and its chemical inhibitor TC-E 5002 overcomes cisplatin-resistance in bladder cancer cells","volume":"21","author":"Lee","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2025.101343_bib23","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.drup.2025.101343_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101059","article-title":"Single-cell transcriptome analysis reveals the association between histone lactylation and cisplatin resistance in bladder cancer","volume":"73","author":"Li","year":"2024","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2025.101343_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100938","article-title":"Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms","volume":"68","author":"Li","year":"2023","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2025.101343_bib26","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1038\/s41586-024-07992-y","article-title":"AARS1 and AARS2 sense L-lactate to regulate cGAS as global lysine lactyltransferases","volume":"634","author":"Li","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.drup.2025.101343_bib27","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/s42255-020-0267-9","article-title":"Glis1 facilitates induction of pluripotency via an epigenome-metabolome-epigenome signalling cascade","volume":"2","author":"Li","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.drup.2025.101343_bib28","doi-asserted-by":"crossref","first-page":"1378292","DOI":"10.3389\/fphar.2024.1378292","article-title":"AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies","volume":"15","author":"Li","year":"2024","journal-title":"Front Pharm."},{"key":"10.1016\/j.drup.2025.101343_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173972","article-title":"Emerging roles of dehydrogenase\/reductase member 2 (DHRS2) in the pathology of disease","volume":"898","author":"Li","year":"2021","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.drup.2025.101343_bib30","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41419-022-05291-w","article-title":"DHRS2 inhibits cell growth and metastasis in ovarian cancer by downregulation of CHK\u03b1 to disrupt choline metabolism","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2025.101343_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202401399","article-title":"Lactylation-Driven IGF2BP3-Mediated Serine Metabolism Reprogramming and RNA m6A-Modification Promotes Lenvatinib Resistance in HCC","volume":"11","author":"Lu","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.drup.2025.101343_bib32","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1089\/ars.2009.2698","article-title":"Redox regulation of DNA repair: implications for human health and cancer therapeutic development","volume":"12","author":"Luo","year":"2010","journal-title":"Antioxid. Redox Signal"},{"key":"10.1016\/j.drup.2025.101343_bib33","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2022.42","article-title":"Lactate, histone lactylation and cancer hallmarks","volume":"25","author":"Lv","year":"2023","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.drup.2025.101343_bib34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/PPO.0000000000000283","article-title":"Targeting Histone methylation in cancer","volume":"23","author":"McCabe","year":"2017","journal-title":"Cancer J."},{"key":"10.1016\/j.drup.2025.101343_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252010982","article-title":"Acetylation of histone H3 in cancer progression and prognosis","volume":"25","author":"Miziak","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2025.101343_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi6696","article-title":"Class I histone deacetylases (HDAC1-3) are histone lysine delactylases","volume":"8","author":"Moreno-Yruela","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.drup.2025.101343_bib37","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/jcmm.13971","article-title":"Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors","volume":"23","author":"Nettersheim","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.drup.2025.101343_bib38","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1038\/s41467-021-25332-w","article-title":"The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma","volume":"12","author":"Ny","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.drup.2025.101343_bib39","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1038\/s41388-022-02379-7","article-title":"AKR1C3 regulated by NRF2\/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma","volume":"41","author":"Pan","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.drup.2025.101343_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176271","article-title":"Moving towards personalized medicine in muscle-invasive bladder cancer: where are we now and where are we going?","volume":"21","author":"Pardo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2025.101343_bib41","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.mce.2018.07.002","article-title":"AKR1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase\/prostaglandin F synthase): roles in malignancy and endocrine disorders","volume":"489","author":"Penning","year":"2019","journal-title":"Mol. Cell Endocrinol."},{"key":"10.1016\/j.drup.2025.101343_bib42","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.2174\/0929867324666170207142740","article-title":"HDACs and HDAC Inhibitors in Urothelial Carcinoma - Perspectives for an Antineoplastic Treatment","volume":"24","author":"Pinkerneil","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.drup.2025.101343_bib43","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.cmet.2023.06.013","article-title":"Hexokinase 2-mediated gene expression via histone lactylation is required for hepatic stellate cell activation and liver fibrosis","volume":"35","author":"Rho","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.drup.2025.101343_bib44","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/s43018-024-00729-w","article-title":"Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial","volume":"5","author":"Roussos Torres","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.drup.2025.101343_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216395","article-title":"Targeting YB-1 via entinostat enhances cisplatin sensitivity of pleural mesothelioma in vitro and in vivo","volume":"574","author":"Schelch","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.drup.2025.101343_bib46","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1158\/1078-0432.CCR-18-1106","article-title":"Divergent biological response to neoadjuvant chemotherapy in muscle-invasive bladder cancer","volume":"25","author":"Seiler","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2025.101343_bib47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12032-022-01770-4","article-title":"Differential molecular mechanistic behavior of HDACs in cancer progression","volume":"39","author":"Singh","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.drup.2025.101343_bib48","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1158\/1078-0432.CCR-23-1795","article-title":"Entinostat Enhances the Efficacy of Chemotherapy in Small Cell Lung Cancer Through S-phase Arrest and Decreased Base Excision Repair","volume":"29","author":"Solta","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.drup.2025.101343_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-016-0279-9","article-title":"Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives","volume":"9","author":"Song","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.drup.2025.101343_bib50","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41419-019-1597-y","article-title":"Targeting HDAC\/OAZ1 axis with a novel inhibitor effectively reverses cisplatin resistance in non-small cell lung cancer","volume":"10","author":"Sun","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.drup.2025.101343_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101248","article-title":"Lactylation in cancer progression and drug resistance","volume":"81","author":"Sun","year":"2025","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.drup.2025.101343_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810030","article-title":"Androgen receptor signaling induces cisplatin resistance via down-regulating GULP1 expression in bladder cancer","volume":"22","author":"Teramoto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drup.2025.101343_bib53","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.drup.2025.101343_bib54","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202310146","article-title":"Targeting the KAT8\/YEATS4 axis represses tumor growth and increases cisplatin sensitivity in bladder cancer","volume":"11","author":"Xie","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.drup.2025.101343_bib55","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1158\/0008-5472.CAN-22-2233","article-title":"NAT10 Drives Cisplatin Chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer","volume":"83","author":"Xie","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.drup.2025.101343_bib56","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/j.apsb.2023.02.001","article-title":"Entinostat, a class I selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Xu","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.drup.2025.101343_bib57","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.7150\/ijbs.91492","article-title":"Histone lactylation: from tumor lactate metabolism to epigenetic regulation","volume":"20","author":"Yu","year":"2024","journal-title":"Int J. Biol. Sci."},{"key":"10.1016\/j.drup.2025.101343_bib58","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2174\/0929867328666211108105214","article-title":"Histone Modifications and their Role in Epigenetics of Cancer","volume":"29","author":"Zaib","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.drup.2025.101343_bib59","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/s41586-019-1678-1","article-title":"Metabolic regulation of gene expression by histone lactylation","volume":"574","author":"Zhang","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.drup.2025.101343_bib60","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41585-024-00857-z","article-title":"Targeting histone modifiers in bladder cancer therapy - preclinical and clinical evidence","volume":"21","author":"Zhang","year":"2024","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.drup.2025.101343_bib61","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1614","article-title":"Histone lactylation bridges metabolic reprogramming and epigenetic rewiring in driving carcinogenesis: Oncometabolite fuels oncogenic transcription","volume":"14","author":"Zhang","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.drup.2025.101343_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102403","article-title":"Aldo-keto reductase 1C3 mediates chemotherapy resistance in esophageal adenocarcinoma via ROS detoxification","volume":"13","author":"Zhou","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drup.2025.101343_bib63","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/onc.2017.383","article-title":"DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma","volume":"37","author":"Zhou","year":"2018","journal-title":"Oncogene"}],"container-title":["Drug Resistance Updates"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764625001463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1368764625001463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:07:12Z","timestamp":1778605632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1368764625001463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":63,"alternative-id":["S1368764625001463"],"URL":"https:\/\/doi.org\/10.1016\/j.drup.2025.101343","relation":{},"ISSN":["1368-7646"],"issn-type":[{"value":"1368-7646","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Entinostat overcomes cisplatin resistance in bladder cancer by promoting H3K18la-mediated DHRS2 expression and nuclear translocation to suppress the AKR1C3-androgen axis","name":"articletitle","label":"Article Title"},{"value":"Drug Resistance Updates","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drup.2025.101343","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101343"}}